From the makers of
Track & Manage All Of Your Investments
Try It Now!
New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
Sanofi-Aventis SA (SNY)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for Sanofi-Aventis SA
A-3 Other
Abstract 3069
Abstract 3069 Activity Mva 5t4 Alone Combination Either
Abstract 4007
Abstract 4067
Abstract 4514
Abstract 4514 Randomized Phase Study S-1 Alone Versus
Abstract 537 Estrogen Receptor Expression Efficacy Docetaxel Early
Abstract 5508
Abstract 5508 Vegf-trap Patients Pts Recurrent Platinum-resistant Epithelial
Abstract 7627 Phase Study Efficacy Safety Intravenous Ave0005
Abstract 9526 Child Matters Program Uicc-sanofi-aventis Partnership Improve
Abstract Lba1008
Abstract Lba5
Abstract Lba5 Final Results Eortc Intergroup Randomized Phase
Acambis
Acambis Plc
Accounting Financial Statement Preparation Procedures
Accounting Transactions Foreign Currencies Individual Accounts
Accounts Committee
Accounts Receivable
Accumulated Other Comprehensive Income
Acellular
Acomplia
Acomplia Recommended Approval European Union
Acomplia Rimonabant
Acomplia Rimonabant Receives Marketing Authorisation European Union
Acquired In-process
Acquired In-process Research Development
Acquisition
Acquisition Advances Emerging Markets Strategy
Acquisitions
Acrobat
Action 2005 Employee Share Ownership Plan
Action Been Undertaken Make Offer Public Notes Described
Active Trial
Active-a Active-i Program Continue
Activity Indication Further Justifies Ongoing Phase Study Trist
Activity Mva 5t4 Alone Combination Either Interleukin-2 Interferon-alpha
Actonel
Actonel Optinate Acrel
Actonel Patent Litigation
Acts-gc Study
Acute Coronary Syndrome
Acute Coronary Syndrome Acs
Acute Coronary Syndrome Undergoing Intervention
Acute Hepatic Failure Severe Liver Injury Some Cases
Adacel Vaccine Development
Additional Disclosures Groups French Gaap Financial Statements
Additional Disclosures Groups Gaap Financial Statements
Additional Information
Address Principal Executive Offices
Adjusted Consolidated Income Statement
Adjusted Consolidated Net Income
Adjusted Earning Per Share
Adjusted Earnings Per Share
Adjusted Eps 528 128162 128106 2005 198 Excluding
Adjusted Eps Excluding Selected 110
Adjusted Eps Growth 150 Excluding Selected
Adjusted Income Statement Excluding Selected
Adjusted Net Income
Adjusted Pro Forma Net Income
Adjusted Pro Forma Results
Adjusted Proforma Basis
Adjustments
Adjustments Consolidated Financial Statements Reflect Application Purchase Accounting
Adjuvant Colon Cancer Setting
Adult Adolescent Boosters
Adults Children Age Older
Advanced Colorectal Cancer Setting
Advanced Non Small Cell Lung Cancer
Aflibercept Vegf Trap
Aflibercept Vegf Trap Oncology
Aflibercept Vegf-trap
After Change Method Accounting Employee Benefits
After Consultation Stock Market Authorities France United States
After End Shareholders Annual General Meeting
After Surgery Patients Resectable Liver Metastases Colorectal Cancer
Against Leading Cause Death Developing Countries
Age
Agreal Product Litigation
Agreement Procter Gamble Pharmaceuticals
Agreement Settle Plavix Litigation Apotex
Aim
Albemarle Arbitration
Albemarle Litigation
Allegra
Allegra Line Products
Allegra Litigation
Allegra Patent Litigation
Allegra Telfast
Allegra-d Fexofenadine Hcl 180 Pseudoephedrine 240 Extended Release
Allergic Conditions
Allergic Rhinitis
Allergies Rise Longer-lasting Allergy Seasons Patients Desire Fast
Alliance
Alliance Agreements Bristol-myers Squibb Bms
Alliance Agreements Organon
Alliance Agreements Pfizer
Alliance Agreements Procter Gamble Pharmaceuticals
Alliance Arrangements Bristol-myers Squibb Bms
Alliances
Allocation Profits
Allocation Shares Purchased Prior 2004 Further Re-allocations
Alopexx Pharmaceuticals Llc
Alopexxs Novel Human Antibody
Alvesco
Alvocidib Refractory Chronic Lymphocytic Leukemia Cll
Amaryl
Amaryl Amarel Solosa
Ambien
Ambien Improved Sleep Quality Impact Daily Activities Mdd
Ambien Patent Litigation
Ambien Zolpidem Tartrate Extended-release Tablets
Ambien Zolpidem Tartrate Product Litigation
Ambitious Drug-monitoring Program Started Africa
Amendments Affecting Class Shareholders Rights
Amortization Impairment Intangibles
Amortization Intangibles
Amortization Other Intangible Assets
Amyris Biotechnologies
Animal Health
Animal Health Merial
Announcement 2005 Transfer Sanofi-aventis 100 Plavix Rights Japan
Annual General Meeting
Annual Meeting
Annual Ordinary Meetings
Annual Payments Participating Share Series Pssa
Annual Payments Pssas
Antithrombotic Therapy
Antoine Ortoli
Apidra
Apidra Insulin Glulisine
Apidra Insulin Glulisine Rdna Origin
Apidra Solostar
Apollo Study Findings
Apotex
Apotex Settlement Claim
Appendix 2005 Adjusted Consolidated Statement Income
Appendix 2005 First-half Adjusted Consolidated Financial Statements
Appendix 2005 First-half Consolidated Income Statement
Appendix 2005 First-half Net Sales Product
Appendix 2005 Full-year Adjusted Consolidated Financial Statements
Appendix 2005 Full-year Net Sales Product
Appendix 2005 Full-year Reconciliations Consolidated Income Statement Adjusted
Appendix 2005 Net Sales Product
Appendix 2005 Reconciliation Consolidated Statement Income Adjusted
Appendix 2009 9-month Net Sales Animal Health Product
Appendix Adjusted Consolidated Income Statements 2005
Appendix Consolidated Net Sales Business Segment
Appendix Definitions Non-gaap Financial Indicators
Appendix Explanatory Notes
Appendix Explanatory Notes Financial Indicators
Appendix Reconciliation Consolidated Income Statement Adjusted 2005
Appendix Reconciliation Proforma Statement Income Adjusted 2003 2004
Appendix Sanofi-aventis Simplified Consolidated Balance Sheets Statement Cash
Appendix Simplified Consolidated Balance Sheet
Appendix Simplified Consolidated Cash Flow Statement
Appendix Simplified Consolidated Statement Cash Flows Balance Sheet
Appendix Trend Selected Adjusted Net Income
Appendix Trend Selected After Tax Adjusted Net Income
Appendix Trends Selected Adjusted Income Statement After Tax
Appendix Trends Selected Adjusted Income Statement Net Tax
Application Change Control Clauses
Applications European Union
Appointments Governance Committee
Approval Based Clinical Trial Tax 324
Approval Based Pediatric Clinical Trial
Approval Dividends
Approval European Union
Approved Europe
Approved European Union
Aprovel
Aprovel Avapro Karvea
Arava Antitrust Litigation
Arch Fam Med
Armour Blood Products Litigation
Arpeggio
Asaq
Asaq Field-monitoring Program
Ascites
Asco
Asco Meeting
Assessment Objectives End 2006
Assets Held Sale
Assets Held Sale Liabilities Related
Assets Liabilities Business Segment
Assets Liabilities Segment
Associates
Assumes Exchange Rate 125 Euro Sensitivity Fluctuations Estimated
Assumption Sanofi-aventis Obligations Aventis
Athena
Athena Study
Atherothrombosis
Atrial Fibrillation
Atrial Fibrillation Flutter
Atrial Fibrillation Flutter Stroke
Atrial Fibrillation Most Frequent Cardiac Arrhythmia Affects Adults
Atrial Fibrillation Patients
Attendance Person
Attendance Shareholders Meetings Proxies Votes Mail
Audit
Audit Committee
Audit Committee Financial Expert
Audit Committee Pre-approval Procedures
Audit Committeee
Australia
Available Japan 2008
Aventis Animal Nutrition
Aventis Behring
Aventis Cropscience
Aventis Inc Hoechst Gmbh Share Purchase Option Plans
Aventis Inc Hoechst Share Purchase Option Plans
Aventis Pharma Limited India
Awards Shares
Awareness Treatment Control
B10 Cash Equivalents
B10 Trade Receivables
B10 Treasury Shares
B101 Provisions Pensions Other Long-term Benefits
B102 Currency Derivatives Used Manage Financial Risk Exposures
B11 Net Deferred Tax Position
B11 Provisions Risks
B11 Publication Clinical Trial Results
B11 Short-term Investments Deposits
B11 Treasury Shares
B12 Filings Marketing Approval European Japanese Authorities New
B12 Net Deferred Tax Position
B12 Provisions Risks
B12 Revenues
B122 Competing Bid Share Capital Zentiva
B13 Cost Sales
B13 Defense Products
B13 Emission Rights
B13 Legal Arbitral Proceedings
B13 Principal Commercial Commitments Collaboration Agreements
B13 Revenue Recognition
B14 Cost Goods Sold
B14 Divestments Acquisitions Alliances
B14 Financial Income Expenses
B14 Legal Arbitral Proceedings
B14 Research Development Expenses
B14 Revenue Recognition
B15 Cost Sales
B15 Income Tax Expense
B15 Other Current Operating Income
B15 Research Development
B151 Financial Expenses
B152 Financial Income
B16 Income Tax Expenses
B16 Other Current Operating Expenses
B16 Other Operating Income Expense Net
B16 Research Development Expenses
B16 Segment Information
B17 Amortization Intangibles
B17 Operating Profit
B17 Other Current Operating Income
B17 Other Operating Income
B17 Segment Information
B18 Amortization Impairment Intangibles
B18 Other Current Operating Expenses
B18 Other Operating Expenses
B18 Restructuring Costs
B19 Amortization Intangibles
B19 Financial Income Expense Net
B19 Impairment Property Plant Equipment Intangibles
B20 Exceptional
B20 Operating Income Before Restructuring Impairment Property Plant
B20 Other Operating Income Expenses
B20 Restructuring Costs
B21 Impairment Property Plant Equipment Intangibles
B21 Income Taxes
B211 Financial Expenses
B212 Financial Income
B22 Employee Benefits
B22 Income Tax Expense
B22 Other Operating Income Expenses
B23 Employee Benefit Obligations
B23 Financial Instruments
B231 Financial Expenses
B232 Financial Income
B24 Earnings Per Share
B24 Income Taxes
B24 Share-based Payment
B241 Stock Option Plans
B242 Employee Share Ownership Plans
B242 Employee Stock Ownership Plans
B25 Earnings Per Share
B25 Employee Benefit Obligations
B26 Segment Information
B26 Segment Reporting
B261 Stock Option Plans
B262 Employee Stock Ownership Plans
B27 Earnings Per Share
B27 Management Capital
B27 New Iasb Standards Interpretations Applicable 2007 Onwards
B28 New Iasb Standards Amendments Interpretations Applicable 2009
B28 New Iasb Standards Interpretations Applicable 2008 Onwards
B28 Segment Reporting
B29 New Iasb Standards Interpretations Applicable 2006 Onwards
B31 Accounting Treatment
B32 Goodwill
B41 Pharmaceutical Research Development
B41 Research Development Not Acquired Business Combination
B42 Other Intangible Assets
B43 Intangible Assets Acquired Business Combination
B61 Impairment Property Plant Equipment Goodwill Intangible Assets
B61 Impairment Property Plant Equipment Intangible Assets
B62 Impairment Investments Associates
B63 Reversals Impairment Losses Charged Against Property Plant
B71 Financial Assets
B71 Share Capital
B72 Derivative Instruments
B73 Impairment Financial Assets
B73 Repurchase Sanofi-aventis Shares
B74 Hedging
B74 Stock Option Plans
B75 Financial Liabilities
B75 Number Shares Used Compute Diluted Earnings Per
B76 Fair Value Financial Instruments
B77 Derecognition Financial Instruments
B81 Financial Assets
B81 Share Capital
B82 Impairment Financial Assets
B82 Market Value Debt
B82 Market Value Debt Net Cash Equivalents
B82 Repurchase Sanofi-aventis Shares
B83 Derivative Instruments
B83 Stock Option Plans
B84 Hedging
B84 Number Shares Used Compute Diluted Earnings Per
B85 Financial Liabilities
B86 Fair Value Financial Instruments
B87 Derecognition Financial Instruments
B88 Risks Relating Financial Instruments
B92 Currency Derivatives Used Manage Financial Risk Exposures
B92 Market Value Debt
Background
Background Pertussis
Barcelona 2006
Barring Major Adverse Events Sanofi-aventis Expects Full-year Adjusted
Based Good First-half Results Barring Major Adverse Events
Basis Consolidation
Basis Preparation
Basis Preparation Financial Information Accounting Policies
Basis Preparation Financial Statements Accounting Policies
Basis Preparation Interim Consolidated Financial Statements
Bcirg
Bcirg 006 Study
Before Appropriation Profit
Beijing Economic Technological Development Area
Believe Developed Sales Useful Measurement Tool Because They
Believe Pro Forma Combined Developed Sales Useful Measurement
Belén Garijo
Bethesda 2007
Better Answer Global Health Needs
Biologically Derived Ingredients Face Consumer Resistance Adversely Affect
Biologically Derived Ingredients Face Patient Resistance Adversely Affect
Biologically-derived Ingredients Face Consumer Resistance Adversely Affect Sales
Biometrics Center Beijing
Biotinylated Idraparinux
Bipar Sciences
Bite Antibodies
Bms Alliance
Board Directors
Board Directors 2008
Board Directors Borrowing Powers
Board Directors Committees
Board Practices
Boards Powers
Bonus Profit Sharing
Bordetella Pertussis
Brazilian Antitrust Claims
Breakdown Sites Between Owned Leased
Breakdown Sites Between Owned Leased Worldwide
Breakdown Sites Function France
Breakdown Sites Function France Worldwide
Breakdown Sites Function Worldwide
Breakdown Sites Nature
Breast Cancer
Brief Description Internal Control Procedures Associated Processes
Bring Greater Flexibility Patients Opportunity Earlier Initiation Insulin
Bristol-myers Squibb
Bristol-myers Squibb Bms
Bristol-myers Squibb Bms Alliance
Bristol-myers Squibb Global Pharmaceutical Related Health Care Products
Bsi-201
Building Long History Allergy Treatment Arena Opportunity Allows
Bulletin Des Annonces Légales Obligatoires
Business Combination Between Sanofi-aventis Aventis
Business Combinations
Business Travel Authorization Expenses Report Procedure
Bylaws
C312 Net Sales Geographic Region
Canada
Cancer
Cancer Facts Figures 2004
Capacities
Cape Town South Africa 2006
Capital Expenditures Divestitures
Capital Leases
Cardiol
Cardiovascular
Cardiovascular Outcomes
Cardiovascular Thrombosis
Cardizem Antitrust Litigation
Case Questions Regarding Settlement Offer
Case Questions Regarding Tendering Shares
Cash Equivalents
Cash Flow
Cash Flow Presentation
Cassiopea Study
Cautionary Statement Regarding Forward-looking Statements
Cayman Islands Taxes
Celanese
Central Group Functions Simplified Reactive Organization
Central Nervous System
Central Nervous System New Approaches Sleep Disorders Depression
Cet Webcast
Chairman Board Directors Report-internal Control
Chairman Chief Executive Officer
Chairman Vice-chairman Board Directors
Challenges Patented Products
Change Accounting Method
Change Consolidation Method Prior Period Recalculated Basis Used
Change Consolidation Percentage Consolidated Entity Prior Period Recalculated
Change Control Anti-takeover
Change Method Consolidation
Change Presentation
Change Proportionate Consolidation Method Equity
Changes Marketing Status Competitive Environment Major Products Adversely
Changes Previous Accounting Policies
Changes Share Capital 2005
Changes Share Capital 2006
Changes Share Capital 2007
Changes Share Capital 2008
Changes Share Capital Between 2005 2006
Changes Shareholders Rights
Chicago Tokyo Japan Paris France 2007-
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Chief Strategic Officer Cso
Child Matters
Children Nasal Symptoms Associated Perennial Allergic Rhinitis
Children Through Age
Chris Viehbacher
Christian Lajoux
Christopher Viehbacher
Chumakov Institute Poliomyelitis Viral Encephalitides
Cipro Antitrust Litigation
Cipro Litigation
Circulation
Cirg
Cirrhotic Ascites
Cisplatin 5-fluorouracil Tpf Regimen Increases Survival Approval Hope
Civil Suits Department Justice Relating Anzemet
Civil Suits Pricing Marketing Practices
Civil Suits-pricing Marketing Practices
Claims Investigations Relating Marketing Practices Competition Law Adversely
Claims Relating Marketing Practices Adversely Affect Business Results
Clariant Specialty Chemicals Business
Clariant-specialty Chemicals Business
Class Action Suits-pricing Marketing Practices
Clexane
Clexane Lovenox
Clexane Lovenox Approved Japan
Clexane Lovenox Enoxaparin
Clin Infect Dis
Clinical Considerations Eloxatin
Clinical Oncology Annual Meeting
Clinical Studies
Clinical Trial
Clinical Trials Rimonabant
Clopidogrel Applications Germany
Clopidogrel Germany
Clostridium Tetani
Cobra Study
Code Ethics
Code Financial Ethics
Collaboration
Collaboration Enables Reach Goal Some Scientists Only Dream
Collaborations Parties Expose Risks They Assert Intellectual Property
Collaborations Parties Expose Risks They Claim Intellectual Property
Collaborative Agreements
Colorectal Cancer
Colorectal Cancer Leading Cause Death
Combinations
Combined Cisplatin Demonstrates Significant Improvement Overall Survival Advanced
Comments Adjusted Proforma Statement Income
Comments Product
Comments Therapeutic Class
Commercial Commitments
Commercial Launch Planned Summer 2009
Commitments Favor Executive Directors Post 2008
Committed Global Polio Eradication Initiative
Committees
Common Stock 2004 Was
Communicating
Community
Comparable Net Sales
Comparable Sales
Comparable-basis Net Sales
Compared Adjusted 2005
Compensation Appointments Governance Committee
Compensation Committee
Compensation Options Shares Awarded Christopher Viehbacher
Compensation Options Shares Awarded Gérard Fur Chief Executive
Compensation Options Shares Awarded Jean-françois Dehecq
Compensation Payable Paid Christopher Viehbacher
Compensation Payable Paid Gérard Fur Chief Executive Officer
Compensation Payable Paid Jean-françois Dehecq
Compensation Pension Arrangements Corporate Officers
Compensation Pension Arrangements Gérard Fur
Compensation Pension Arrangements Jean-françois Dehecq
Compensation Senior Management
Competition
Compliance
Components Internal Control
Composition Board Directors
Composition Board Directors 2007
Composition Operation
Compounds Currently Later-stage Development Thrombosis
Conference Call
Conference Call Held Tuesday 2005 400 Cet
Confined Intensive Care Unit
Confirm-1
Confirmation 2008 Guidance
Conjugate Vaccine Technology
Consent Independent Registered Public Accounting Firm
Consolidated Balance Sheet
Consolidated Balance Sheet Debt
Consolidated Balance Sheets
Consolidated Balance Sheets Assets
Consolidated Balance Sheets Liabilities Equity
Consolidated Cash Flow
Consolidated Cash Flow Net Debt
Consolidated Cash Flow Statement Balance Sheet 2008 Refer
Consolidated Cash Flows Balance Sheet 2005
Consolidated Financial Information 2004 Includes Statements Aventis Subsidiaries
Consolidated Financial Statements
Consolidated Financial Statements Other Information
Consolidated Financial Statements Presented Appendix 3the Date
Consolidated Gross Profit
Consolidated Net Debt
Consolidated Net Financial Income Expense
Consolidated Net Income Loss
Consolidated Net Income Loss Attributable Equity Holders
Consolidated Net Sales
Consolidated Net Sales Sanofi-aventis
Consolidated Operating Loss
Consolidated Statement Cash Flow Balance Sheet 2007
Consolidated Statement Cash Flows
Consolidated Statement Cash Flows Balance Sheet
Consolidated Statement Cash Flows Balance Sheet 2006
Consolidated Statement Cash Flows Balance Sheet 2008
Consolidated Statements Cash Flows
Consolidated Statements Other Financial Information
Consolidated Statements Recognized Income Expense
Consumer Australia Now Completed
Contact
Contact Anne Bancillon
Contact Media Inquiries
Contacts
Context Worldwide Financial Crisis Liquidity Constrained
Contingencies Arising Certain Business Divestitures
Contingent Csl Consideration
Contraindications Precautions
Contribution Equity Investees
Controlling Mealtime Blood Sugar Spikes Crucial Part Managing
Controls Procedures
Conversion Aventis Stock Options
Conveyance Transfer Shares
Copaxone
Coronary Artery Disease Acute Syndrome
Coronary Artery Disease Cad Acute Syndrome Acs
Corporate
Corporate Governance
Corporate Purposes
Corynebacterium Diphtheriae
Cosima
Counterfeit Products Harm Business
Counterfeit Products Harm Business Sanofi-aventis
Counterparty Risk
Crc Rule 2000-06
Crc Rule 2002-10
Credit Facilities
Critical Accounting Reporting Policies
Critical Limb Ischemia Severe Costly Condition Following Episode
Crucell
Cumulative Preference Shares Series
Currency Forward Options Contracts
Current-oasis Trial
D10 Accounts Receivable
D10 Other Current Assets
D10 Short-term Investments Deposits
D11 Deferred Income Taxes
D11 Financial Assets Current
D11 General Description
D11 Net Sales
D11 Other Current Assets
D110 Impairment Property Plant Equipment Intangibles
D111 Gains Losses Disposal Litigation
D111 Net Sales Business Segment
D112 Net Sales Geographic Region
D112 Operating Income
D113 Financial Income Expenses
D113 Worldwide Presence Plavix Aprovel
D114 Income Before Tax Associates
D115 Income Tax Expense
D116 Share Profit Loss Associates
D117 Net Income
D118 Net Income Attributable Minority Interests
D119 Net Income Attributable Equity Holders
D12 Cash Equivalents
D12 Financial Assets Current
D12 Other Revenues
D121 Share Capital
D122 Change Accounting Method
D123 Adjustments Shareholders Equity Related Merger Between Sanofi
D124 Impact Acquisition Aventis Shareholders Equity
D126 Repurchase Sanofi-aventis Formerly Sanofi-synthélabo Shares
D13 Cash Equivalents
D13 Gross Profit
D13 Minority Interests
D13 Pro Forma Financial Information
D13 Pro Forma Information
D131 Share Capital
D132 Adjustments Shareholders Equity Related Sanofi Synthélabo Merger
D133 Repurchase Sanofi-aventis Shares
D134 Reduction Share Capital
D135 Cumulative Translation Differences
D136 Recognized Directly Shareholders Equity
D14 Debt
D14 Research Development Expenses
D15 Selling General Expenses
D151 Provisions Pensions Other Benefits
D151 Share Capital
D152 Capital Increase Reserved Employees Employee Share Ownership
D152 Restructuring Provisions
D153 Adjustment Shareholders Equity Related Sanofi Synthélabo Merger
D153 Capital Increase Reserved Employees Employee Share Ownership
D153 Other Provisions
D154 Other Long-term Liabilities
D154 Other Non-current Liabilities
D154 Repurchase Sanofi-aventis Shares
D155 Reduction Share Capital
D156 Cumulative Translation Differences
D157 Other Recognized Directly Equity
D157 Recognized Directly Equity
D159 Number Shares Used Compute Diluted Earnings Per
D16 Minority Interests
D16 Other Current Liabilities
D16 Other Operating Income Expenses
D17 Amortization Intangibles
D17 Debt Cash Equivalents
D17 Short-term Debt
D18 Derivative Financial Instruments
D18 Personnel Costs
D182 Restructuring Provisions
D183 Other Provisions
D184 Other Non-current Liabilities
D19 Other Current Liabilities
D19 Other Current Operating Income
D19 Restructuring Costs
D20 Derivative Financial Instruments Market Risks
D20 Other Current Operating Expenses
D202 Commitment Buy Out Shares Subsidiaries
D202 Equity Derivatives
D203 Other Commercial Commitments
D21 Personnel Costs
D21 Restructuring Costs
D22 Adjusted Net Income
D22 Legal Arbitral Proceedings
D22 Other Operating Income Expense Net
D22 Other Operating Income Expenses
D23 Adjusted Earnings Per Share Eps
D23 Financial Income Expense Net
D231 Financial Income
D232 Financial Expenses
D24 Exceptional
D24 Income Tax Expense
D24 Personnel Costs
D25 Other Current Operating Income
D25 Other Operating Income
D251 Business Segments
D26 Minority Interests
D26 Other Current Operating Expenses
D26 Other Operating Expenses
D261 Repurchase Hoechst Minority Shareholders
D262 Acquisition Commercial Rights Plavix Japan
D263 Disposal Interest Wacker-chemie Gmbh
D27 Related Party Transactions
D27 Restructuring Costs
D28 Gains Losses Disposals Litigation
D28 Other Operating Income Expenses
D28 Split Net Sales
D29 Financial Income Expenses
D29 Segment Information
D291 Financial Expenses
D292 Financial Income
D30 Income Tax Expense
D31 Share Profit Loss Associates
D32 Minority Interests
D32 Net Income Attributable Minority Interests
D33 Related Party Transactions
D34 Split Net Sales
D351 Business Segments
D352 Information Geographical Segment
Daiichi Pharmaceutical
Daptacel Vaccine
Data Answer World Health Organization Calls Demonstration Cross-reactivity
Data Easd Suggests Better Glycaemic Control Possible Using
Data Exclusivity Protection
Data Presented Asco 2007 Highlights Sanofi-aventis Commitment Oncology
David Williams
Ddavp Antitrust Litigation
Ddavp Litigation
Ddavp Patent Litigation
Debt Cash Equivalents
Debt Net Cash Equivalents Currency Value Redemption
Decreases Share Capital
Deep Vein Thrombosis Pulmonary Embolism
Defense Lovenox Patent United States
Defense Plavix Patent United States
Defense Plavix Patent United States Europe
Defense Products
Deferred Income Tax Above Adjustments
Deferred Income Tax Effect Above Adjustments
Deferred Tax Equity Investees
Deferred Tax Intercompany Margins
Deferred Tax Liability Acquired In-process Research Development
Deferred Tax Related Acquired Stock Options
Deferred Taxes
Deferred Taxes Equity Investees
Definition Objectives Internal Control
Delays Onset Reduces Occurrence Repeat Heart Attacks Window
Deliberations Board
Demonstration Good Cardiovascular Tolerability Alfuzosin
Dengue Fever
Depakine
Depend Parties Manufacture Supply Substantial Portion Raw Materials
Depend Parties Manufacturing Active Ingredients Some Products Substantial
Depend Parties Marketing Some Products Act Ways Harm
Depend United States Market Significant Part Current Future
Derecognition
Derivative Financial Instruments
Derivative Instruments
Detail Material Impacts 2004 Proforma Statement Income Arising
Developed Sales
Developed Sales Aprovel Avapro Karvea
Developed Sales Plavix Iscover
Developing Worldwide Market Presence Controlling Operating Results
Development
Development Programs Stopped Since 2005
Development Stage
Developments Relating Defense Sanofi-aventis Products
Developments Relating Expansion Presence Japan
Developments Relating Filings Marketing Approval European Healthcare Authorities
Diabetes
Diabetes Care
Diabetes Mellitus
Diabetologia
Differences Presentation Between French Gaap
Differences Resulting Application Ifrs
Difficile
Difficult Environment Another Growth Adjusted Eps Excluding Selected
Diphtheria
Diphtheriae
Directors
Directors Age Limits
Directors Compensation
Directors Senior Management
Directors Share Ownership Requirements
Disclosure Controls Procedures
Discontinuation Commercialization Copaxone Sanofi-aventis North America Effective 2008
Discounting Long-term Provisions
Discovery Research
Discovery Research Operations
Discovery Stage
Disease Endemic United States
Distribution Dividends
Distribution Formula
Diversified Global Leader Healthcare
Divestment Exubera Rights Interest Diabel
Divestment Notre Dame Bondeville Site
Divestments
Divestments Acquisitions Alliances
Dividend
Dividend 151 Increase 128175 Per Share Submitted Approval
Dividend Increase 151 128175 Per Share Paid
Dividends
Dividends Ordinary Shares
Division Anesthesia Analgesia Rheumathology Products
Division Cardiovascular Renal Products
Dnd
Docetaxel Injection Concentrate
Documents Display
Donna Vitter
Dronedarone
Dronedarone Multaq
Dronedarone Press Office Http Wwwdronedarone-atrial-fibrillation-pressofficecom References
Dvt
Dyax
Dystar
E3200
Earnings Per Share
Earnings Per Share Attributable Sanofi-aventis Shareholders
Earnings Per Share Eps
Ectrims
Edmonton Canada Paris France 15th 2005
Effect Changes Scope Consolidation
Eligard Patent Litigation
Eloxatin
Eloxatin -based Therapy Central Research Targeted Agents Metastatic
Eloxatin Europe
Eloxatin Oxaliplatin Patent Litigation
Eloxatin Patent Litigation
Eloxatine
Eloxatine European Patent Litigation
Eloxatine Patent Litigation
Employee Benefits
Employee Savings Schemes
Employee Savings Schemes Collective Retirement Plan
Employee Share Ownership
Employee Stock Options
Employees Function
Employees Geographic Area
Employees Main Category Function
Encouraged Results Seeing Aflibercept Vegf Trap Especially Evidence
Encouraging Data Show Potential Pre-pandemic Vaccine Offer Broad
Encouraging Results Vegf Trap Aflibercept Highlighted Asco 2007
End 2007
Enforceability Civil Liabilities
Engl Med
Enoxaparin
Environment
Environmental Liabilities Compliance Costs Significant Adverse Effect Operating
Environmental Liabilities Compliance Costs Significant Adverse Effect Results
Eortc 24971 Tax 323 Study
Eortc 24971 Tax 323 Study Identify Neoadjuvant Chemotherapy
Eplivanserin Ciltyri
Eplivanserin Sleep Maintenance Insomnia
Epoc Study
Epoc Study Ambitious Trial Largest Clinical Kind Conducted
Equity Derivative Instruments
Equity-accounted Companies
Erbb3
Estate Gift Taxes Transfer
Estimates
Etal
Ethical Charter Purchasing
Eur
Eur Heart
Eur Respir
Euridis Adonis
Eurolist Market
Euronext Paris Market
Europe
Europe North America
European Commissions Pharmaceutical Sector Inquiry Lead Significant Legislative
European Expands Indication Plavix Clopidogrel Bisulfate Offering New
European Fines
European Imposes Fine Certain Mcaa Producers
Euros
Evaluation Board Procedures
Event Subsequent Balance Sheet Date 2007
Events Subsequent Balance Sheet Date 2008
Events Subsequent Balance Sheet Date 2009
Except Patients Suffering Ongoing Major Depression
Exceptional
Exchange Controls
Exchange Non-monetary Assets
Exchange Rate Information
Exchange Rates
Excluding Net Sales Allegra Amaryl United States
Excluding Selected
Excluding Selected 2005 2006 Include 128384 Post-tax Gain
Excluding Selected 2005 2006 See Appendix Eps Risen
Excluding Selected Adjusted Net Income Was 1281797 145
Excluding Selected Adjusted Net Income Was 1283504 173
Exclusive Collaboration Discovery Pi3k Inhibitors
Executive Committee
Executive Committee Management
Executive Vice President Pharmaceutical Operations
Exelixis
Exemptions Exceptions Ifrs
Exhibits
Existing Option Plans 2006
Existing Option Plans 2007
Existing Option Plans 2008
Expand Strategic Antibody Collaboration
Expenditure Commitment Authorization Procedure
Expert Audits
Expert Opinion Drug Delivery
Explore
Extension Indication Sought Pediatric Population United States Project
Exubera Alliance
F33 Pensions Postretirement Benefits
F34 Earnings Per Share
F35 Accumulated Other Comprehensive Income
F36 Recent Accounting Pronouncements
Face Uncertainties Over Pricing Pharmaceutical Products
Face Uncertainties Over Pricing Reimbursement Pharmaceutical Products
Facility Shanghai
Fact Blood Sugar Levels Reduced Along Weight Loss
Fail Adequately Renew Product Portfolio Whether Through Own
Fair Value
Fair Value Long-term Debt
Fda Approval Significant Milestone Evaluation Treatment Options Patients
Fda Approves Lovenox Enoxaparin Sodium Injection Most Severe
Fifth Consecutive Dose
Fight Fatal Disease
Finalization Preliminary Purchase Price Allocation
Finance
Finance Leases
Financial Accounting Standards Board Fasb Recently Issued Following
Financial Assets
Financial Assets Non-current
Financial Calendar
Financial Code Ethics
Financial Commitment Related Offer Zentiva Shares
Financial Foreign Exchange Derivatives 2005
Financial Foreign Exchange Derivatives 2006
Financial Foreign Exchange Derivatives 2007
Financial Foreign Exchange Derivatives 2008
Financial Foreign Exchange Risk
Financial Income Expenses
Financial Information
Financial Instruments
Financial Investment Authorization Procedure
Financial Liabilities
Financial Presentation Alliances
Financial Statements Other Communications Shareholders
Financial Statements Presented Accordance Ias
Financial Timetable
Financing Aventis Acquisition
Financing Aventis Acquisition 2004 Refinancing Debt 2005
Financing Controlling
Financing Treasury Procedures
First-half Business Net Income
First-half Consolidated Financial Statements Been Subject Limited Review
First-half Net Sales
First-half Net Sales Product
Fluctuations Currency Exchange Rates Adversely Affect Results Operations
Flupan
Fluzone Vaccine
Focus Biologics
Following Market Share Ranking Information Based Sales Data
Foreign Currency Translation
Foreign Currency Translation Financial Statements Subsidiaries
Foreign Exchange Fluctuations Adversely Affect Dollar Value Adss
Form
Form Shares
Forward Looking Statement
Forward Looking Statements
Forward Looking Statements Merck
Forward Looking Statements Regeneron
Forward Looking Statements Regeneron Pharmaceuticals Inc
Forward Looking Statements Sanofi-aventis
Forward Looking Statements Schering-plough
Forward-looking Statements
Forward-looking Statements -sanofi-aventis
Forward-looking Statements Regeneron
Forward-looking Statements Sanofi-aventis
Fov 1101 Prednisporin
Fov 2302
Fov 2304
Fovea Pharmaceuticals
France
France Heart Sanofi Pasteur Industrial Operations
Free Translation French Language Original
French Descriptive Report Internal Controls
French Gaap
French President Nicolas Sarkozy State Visit China
French President Nicolas Sarkozys State Visit
French Taxes
Full
Full-year
Full-year Adjusted Eps Growth Least
Full-year Demonstrated Ability Deliver Eps Growth Penalized Generics
Full-year Guidance
Full-year Net Sales
Full-year Net Sales Product
Further Development Other Types Cancer
Further List Description Risks Uncertainties Found Pfizers Annual
Further Positive Phase Results Eplivanserin
Future Events
Future Joint Venture Global Leader Animal Health
Ga-epo Patent Litigation
Gaap Reconciliation
Gaap Reconciliation Presentation Differences
Gains Losses Disposal Litigation
Gains Losses Disposals Litigation
Gastric Cancer
Gastric Stomach Cancer
Gender Discrimination
General
General Informations
General Meeting Shareholders
General Policy
General Shareholders Meetings
Generic Versions Some Products Approved Sale Major Markets
Generics
Geographical Split 2009 First-half Net Sales Vaccines Segment
Germany
Gilles Brisson
Gilles Lhernould
Global Focused Organizations Discovery Development
Global Media Contact
Global Media Relations
Glossary Patent Terminology
Glycemic Control Between Patients Using Lantus Versus Detemir
Gmt Conference Call Webcast
Good 2009 Performance
Good Performance 2009
Good Sales Growth Despite Introduction Generics Products
Goodwill
Goodwill Amortization
Government Investigations Competition Law Regulatory Claims
Government Investigations Plavix Settlement
Government Investigations Pricing Marketing Practices
Government Investigations-pricing Marketing Practices
Government Readiness Program
Gregory Irace
Gross Profit
Group Internal Audit
Groups Commitments
Growing Threat
Growth Net Sales Expressed Constant Structure Basis Exchange
Guarantees
Guarantees Given
Guarantees Received
Guidance
Guidance 2006 Raised Basis First-half Results
Guidance Raised
Guidance Raised Based Good Results Achieved 2007 Full-year
Guidance Reiterated
Gérard Fur
Haemophilus Influenza
Haemophilus Influenzae
Half
Half 2005
Half 2006
Half 2007
Half 2008
Half-year Management Report
Hangzhou Binjiang New Development Zone
Hanspeter Spek
Head Neck Cancer
Head Neck Cancer Deadly Disease
Health
Health Outcomes Treatment Satisfaction Patients Using Lantus Versus
Health Safety Environment
Health Safety Environment Hse
Healthcare Costs Patients Using Lantus Therapy
Heart Disease Stroke Statistics 2006 Update
Hedging
Heinz-werner Meier
Help Patients Diabetes Improve Glycemic Control
Hib
Hib Disease
Highlighted World Congress Cardiology
Highlights Half 2005 Pharmaceuticals Business
Highlights Half 2005 Vaccines Business
Highlights Improved Offer
History Development
Hiv
Hoechst
Hoechst Gmbh Share Purchase Option Plans
Hoechst Shareholder Litigation
Hold Adss Rather Shares Difficult Exercise Some Rights
Holding Shares
Hospital-acquired Resistant Infections
Http Eceuropaeu Internal Market Accounting Ias Enhtm
Http Wwwcopaxonecom Indexhtml
Hub Global Health
Human Concludes Changes Prescribing Advice Necessary
Human Vaccines
Human Vaccines Activity
Hypertension
Idraparinux
Ifrs Exemptions Exceptions
Ifrs Project
Image
Immunization Recommendations
Impact Exchange Rates
Impact Ifrs
Impairment
Impairment Intangible Assets
Impairment Investments
Impairment Property Plant Equipment Intangibles
Implementation Improved Offer
Implementation New Model
Implementation Offer
Important Information
Important Partnerships
Important Risk Information
Important Safety Information
Improved Blood Sugar Control Plus Weight Loss Achieved
Improved Offer
Improved Offer Zentiva Unanimous Backing Zentivas Board Directors
Ims Consolidated Net Sales Presented
Ims Data Related Sanofi-aventis Not Include Vaccines
In-process Research Development Acquired Part Business Combination
Inclusive
Income Before Tax Associates
Income Equity Investees Net
Income Presented Appendix
Income Statements 2004 Respectively Adjusted Net 2005 Was
Income Tax Expense
Income Tax Expenses
Income Taxes
Inconclusive Conflicting Data
Increase 2007 Full-year Earnings Growth Guidance
Increase 2008 Guidance
Increase 2008 Guidance See Page
Increase 2009 Guidance
Increase Breaks Down Following Components 128
Increases Share Capital
Incurred Substantial Debt Connection Acquisition Aventis Limits Business
Independent Registered Public Accounting Firms
Index
Index Financial Statements
Indicate Check Basis Accounting Registrant Used Prepare Financial
Indication
Individual Shareholders
Induces Robust Seroprotective Antibody Response Children Adults
Industrial Relations
Industrial Sites
Industrial Sites Pharmaceutical Activity
Infect Dis Med Microbiol
Influenza
Influenza H1n1 2009 Monovalent Vaccine
Influenza Immunization
Influenza Overview
Influenza Vaccine Production Sanofi Pasteur
Influenza Vaccines
Information Enquiries Please Contact
Information Legal Arbitration Proceedings
Information Relating Sanofi-aventis Combined General Meeting 2007
Information Reporting Backup Withholding
Information Reporting Backup Withholding Tax
Information Systems Usage Charter
Informations Please Visit
Infraserv Höchst
Ingrid Goerg-armbrecht
Initial Order Bulk Vaccine Valued 190
Insomnia
Institute Oneworld Health
Institutional Investors Analysts
Insulin Glargine Rdna Origin
Insulin Glulisine Rdna Origin
Insulin Glulisine Rdna Origin Injection
Insulin Lispro Part Basal-bolus Regimen
Insulin Therapy People Type Diabetes Generally Initiated Very
Insurance
Insurance Risk Coverage
Insuring
Intangible Assets
Integration
Integration Committees
Integration New Groups Activities Presents Significant Challenges Result
Interest Rate Forward Options Contracts
Interest Rate Risk
Interest Vegf-trap Driven Unique Characteristics High Potential Most
Interim Analysis Novel Regimen Taxotere Without Anthracyclines Appears
Interim Analysis Phase Study Shows Taxotere -based Regimens
Interim Results Following Initial Dose Vaccine
Internal Audit Charter
Internal Control Documentation Assessment Program Processes Contributing Preparation
Internal Control Documentation Evaluation Program
Internal Medicine
International Development
International Financial Reporting Standards Adoption
International Financial Reporting Standards Ifrs
Intra-dermal Route Vaccination
Introduction
Introduction Key Figures Half 2006
Inventories
Inventory Costs
Invest Substantial Sums Research Development Order Remain Competitive
Investments Advances Equity Investees
Investments Advances Non-consolidated Companies
Investments Associates
Ionamin Fen Phen Litigation
Irrevocable Purchase Commitments
Irrevocable Purchase Obligations
Italy
Japan
Japanese Phase Clinical Trial
Jean-claude Armbruster
Jean-claude Leroy
Jean-françois Dehecq
Jean-marc Podvin
Jean-michel Lévy
Jean-philippe Santoni
Jean-pierre Kerjouan
Karen Linehan
Karen Linehan General Counsel 174 Avenue France 75013
Ketek
Ketek Cause Visual Disturbances Particularly Slowing Ability Accommodate
Key Figures Half 2007
Key Figures Half 2008
Key Milestone Preparing Pandemic Response Fall
Key Research Areas
Kroger Antitrust Claim
Laboratorios Kendrick
Lactacyd
Lancet
Lantus
Lantus Insulin Glargine Rdna Origin
Lantus Insulin Glargine Rdna Origin Injection
Lantus Regimen Was Associated Reduced Risk Hypoglycemia Fewer
Lantus Solostar
Large Majority
Largest Shareholders Own Significant Percentage Share Capital Voting
Latin America Asia
Laurence Debroux
Legal Reserve
Legend Pharmaceutical Manufacturing Chemical
Liability Further Capital Calls
License Agreements
License Development Agreements
License Income Government Levies
Licensure Nations Vaccine Significant Milestone Pandemic Preparedness
Light Fully Human Monoclonal Antibody
Light Molecule
Limits Placed Board Powers Chief Executive Officer
Liquidation Rights
Liquidity
Liquidity Capital Resources
Liquidity Risk
List
List Appendices
Litigation
Lock-up Period Shares Obtained Exercise Stock Options Chairman
Lock-up Period Shares Obtained Exercise Stock Options Disposition
Long-term Debt
Long-term Receivables Other Deferred Charges
Looking Forward Developing Collaboration Oxford Biomedica
Lovenox
Lovenox Antitrust Litigation
Lovenox Clexane
Lovenox Clexane Europe
Lovenox Patent Infringement Suit Decided Against Sanofi -aventis
Lovenox Patent Litigation
Lovenox Patent Trial Update
Lovenox Reissue Generic Filing
Lovenox Safety Syringe
Lung Cancer
Lung Cancer Study
Lyon France 2005
Lyon France 2006
Lyon France Swiftwater Usa 2005
Ma888
Main Areas
Main Developments Portfolio
Main Events
Main Events Half Vaccines Business Related H5n1 Pandemic
Main Financing Debt Reduction Transactions Period
Main Included Financial Assets Non-current
Main Vaccines Products
Major Products
Malaria Patients Each
Management
Management Committee
Management Control Procedures
Management Type Diabetes Not Only Focus Controlling Blood
Managerial Committees
Managing Human Resources
Managing Information Systems
Managing Legal Affairs
Mandatory Offers Subsequent Acquisition
Mandatory Offers Subsequent Acquisition Aventis
Manufacture Products Technically Complex Supply Interruptions Caused Unforeseen
Manufacture Products Technically Complex Supply Interruptions Product Recalls
Manufacturing Base Hangzhou
Marc Cluzel
Marie-hélène Laimay
Market Value Debt
Market Value Debt Net Cash Equivalents
Marketable Investment Securities
Marketing Distribution
Markets
Material Contracts
Material Impacts Application Fair Value Acquisition Accounting Combination
Material Impacts Application Purchase Accounting Acquisition Follows
Material Impacts Application Purchase Accounting Aventis Acquisition Restructuring
Material Impacts Arising Fair Value Acquisition Accounting Follows
Mcaa Industry Litigation Investigation
Measurement Date Securities Issued
Measurement Impairment Loss Intangible Assets Other Goodwill
Measurement Stock Option Plans
Media Briefing Webcast 400
Media Contact
Media Contacts
Media Relations
Medications Alone
Medicines Malaria Venture
Medley
Medley Brazil
Meeting Committee
Meningitis
Meningitis Pneumonia Vaccines
Meningitis Program
Meningococcal Disease
Meningococcal Meningitis Major Public Health Problem Approximately 500000
Merck
Mercks Interest Merial
Merger Sanofi Group Synthélabo
Merial
Merrimack
Messer Griesheim Gmbh
Metabolic Disorders
Metabolism
Methionine Antitrust Litigation
Method
Methodology
Michel Labie
Micromet Inc
Milan 2005
Minimizing Toxicity
Minority Interests
Minutes
Mm-121
Mmwr
Monoclonal Antibodies
Monoclonal Antibody Oncology
Moraxella Catarrhalis
Moreover People Europe United States Suffer Chronic Kidney
Mosaic
Motion Filed Preliminary Injunction Plavix Patent Infringement Case
Mri
Multaq Dronedarone
Multiple Sclerosis
Multiple Sclerosis Most Common Cause Disability Young Adults
Mycoplasma Pneumoniae
Mérieux Alliance
Nanchang Plants Expansion Project
Nasacort
Nasacort Patent Litigation
National Surgical Adjuvant Breast Bowel Project Nsabp Protocol
Nci Studies
Nearly Cumulative Synergies Delivered End 2005
Neisseria Meningitidis
Net Debt
Net Debt Currency
Net Debt Type Value Redemption
Net Financial Expense
Net Financial Income Expense
Net Income
Net Income Attributable Equity Holders
Net Income Attributable Minority Interests
Net Other Operating Income
Net Sales
Net Sales 110 Comparable Basis
Net Sales 128 6853m Comparable Basis Down Reported
Net Sales Business Segment
Net Sales Business Segment Human Vaccines
Net Sales Business Segment Pharmaceuticals
Net Sales Geographic Region
Net Sales Geographical Region
Net Sales Human Vaccines
Net Sales Product
Net Sales Product -reported-basis Growth
New 2005 Stock Subscription Option Plan Granted Sanofi-aventis
New 2006 Stock Subscription Option Plan Granted Sanofi-aventis
New Anti-arrhythmic Drug Approved European Union Last
New Committees 2008
New England Journal Medicine
New Facility Increase Production Capacity
New Formulation Been Developed Aim Improving Vaccine Effectiveness
New Indication Enoxaparin Now Applicable Across Full Spectrum
New Interpretations
New Lantus Solostar Test Results Published
New Operating Models
New Organization Announced 2007
New Products Portfolio
New Rapid-acting Insulin Analog Now Available United States
New Solid Tumor Bite Antibody
New Standards Amendments Interpretations Applicable 2008
New Standards Interpretations Applicable 2006
New Standards Interpretations Applicable 2007
New Standards Interpretations Subsequent Application
New Tax Distribution Regime
New Vaccine Against Polio Decades Used Egypt Part
New Vaccine Targets
New York
New York 2005
Nicole Cranois
Notes
Notes Pro Forma Financial Information
Notes References
Notice General Shareholders Meetings
Notice Shareholders Meetings
Number Employees
Nutraceuticals Otc Division Australia
Obese Overweight Patients
Objective Definition Internal Control
Objectives Derivative Financial Instruments
Obligation Acquire Hoechst Aktiengesellschaft Shares
Obligations Directors
Observed Pro-arrhythmia
Observers Censeurs
Oenobiol
Offer
Offer Listing Details
Offer Price
Olivier Charmeil
Olivier Jacquesson
Oncology
Oncology Immunology
Oncology Very Ambitious Program Studies Accelerate Market Access
Ongoing Cost Adaptation Measures
Ongoing Transformation Sanofi-aventis
Only Extended-release Prescription Sleep Medication Indicated Induction Maintenance
Opening Organization Outside World
Operating Income
Operating Income Before Restructuring Impairment Ppe Intangibles Gains
Operating Income Before Restructuring Impairment Property Plant Equipment
Operating Income Current
Operating Leases
Operating Profit
Operating Results
Operational Foreign Exchange Derivatives
Operational Foreign Exchange Derivatives 2006
Operational Foreign Exchange Derivatives 2008
Operational Foreign Exchange Risk
Operations Board Directors
Operations Committee
Opticlick Patent Litigation
Opticlik Patent Litigation
Option Additional Doses
Options Purchase Group Shares
Options Subscribe Group Shares
Organization Adjustments
Organizational Audits Conducted Pharmaceuticals Operations Directorate
Organizational Structure
Organizing Group
Osteoporosis
Otc
Other
Other Adjustments
Other Blood Products Litigation
Other Business Combinations
Other Current Assets
Other Current Operating Income
Other Current Operating Income Expenses
Other Developments
Other Foreign Exchange Risks
Other Highlights Half 2005 Included
Other Intangible Assets
Other Legal Matters Adverse Outcomes Changes Law Material
Other Legal Matters Adverse Outcomes Material Effect Business
Other Litigation Arbitration
Other Long-term Investments
Other Long-term Obligations
Other Operating Income Expense
Other Operating Income Expenses
Other Participants
Other Pharmaceutical Products
Other Products
Other Reclassifications
Other Required Applicable Law Anofi-aventis Not Undertake
Other Required Applicable Law Sanofi-aventis Not Undertake Obligation
Other Revenues
Other Segment Information
Other Serious Infectious Diseases
Other Significant Changes 2004
Other Significant Events
Other Standards
Other Study Results Protocol
Other Vaccines
Outlook
Outlook 2005
Ovarian Cancer
Ovarian Study
Over Euros Invested
Over People Worldwide Suffer Alzheimers Disease
Over Polio-free Countries Using Ipv
Overview
Ownership Securities
Ownership Shares Non-french Persons
Oxford Biomedica
Pad
Pandemic Influenza
Pandemic Influenza Overview
Pandemic Influenza Vaccine
Panenza
Panenza Humenza
Paragraph Commercial Code
Paris
Paris 2004
Paris 2005
Paris 2006
Paris 2007
Paris 22nd 2006
Paris France 2005
Paris France 2006
Paris France 2006 Apotex Corp Announced Was Launching
Paris France 2007
Paris France 2007 8211
Paris France 2008 Sanofi-aventis Announced Chris Viehbacher Taken
Paris France Geneva Switzerland 2005
Paris France Jerusalem Israel 2007
Paris France New York 2006
Paris France New York Toronto 2006
Paris France Oxford 2007
Paris France Princeton 2006
Paris France Princeton Aug 2006
Paris France Princeton New Jersey 2006
Paris France San Antonio Usa 2006
Paris France Septembre 2008
Paris France Tarrytown 2007
Paris France Tokyo Japan 2007
Paris France-july 2008- Sanofi-aventis Announces Today Returning Territory
Paris New York 2005
Paris San Antonio 8th 2005
Paris Tokyo- 2005
Participating Shares
Participating Shares Series
Partnerships Access Medicines
Past Decade Lot Research Been Conducted Find Alternative
Patent Infringement Case
Patent Litigation
Patent Protection
Patents
Patents Infringed Infringe Others
Patients Atrial Fibrillation
Patients Atrial Fibrillation Flutter
Patients Treated Insulin
Paying-up Libération Shares
Pci-extract Timi Study
Pediar Infect Dis
Pediatric Adolescent Adult Booster Combination Vaccines
Pediatric Combination Adolescent Adult Booster Vaccines
Pediatric Combination Polio Vaccines
Pediatric Combination Poliomyelitis Polio Vaccines
Pediatric Extension
Pension
Pensions
Pensions Post Retirement Benefits
Pensions Post-retirement Benefits
Pensions Unrecognized Actuarial Gains Losses
Per Share Paid 21st
Percutaneous Coronary Intervention Pci
Performance
Performance Buoyed Key Growth Drivers
Periods Exclude Impact Exchange Rates Recalculating Sales Earlier
Persons Holding Adss Rather Shares Difficulty Exercising Certain
Pertussis
Pfizer
Pfizer Disclosure Notice
Pfizer Disclosure Notice Information Contained Release 2005 Assumes
Phage Display Technology
Pharmaceutical Activity
Pharmaceutical Industry Antitrust Litigation
Pharmaceutical Operations Europe Excluding France Germany
Pharmaceutical Research Development
Pharmaceuticals
Pharmacovigilance
Phase Development Program Aflibercept
Phase Studies Aflibercept Combination Chemotherapy
Phase Studies Aflibercept Symptomatic Malignant Ascites Sma
Phase Study
Phase Study Single-agent Aflibercept Advanced Ovarian Cancer
Phase Trial Trovax High-dose Interleukin-2 Metastatic Renal Cancer
Phase Trial Trovax Interferon-alpha Metastatic Renal Cancer
Phase Trial Trovax Low-dose Interleukin-2 Metastatic Renal Cancer
Philippe Barquet 670486128
Philippe Fauchet
Philippe Peyre
Pi3k Inhibitors
Pierre Chancel
Planning Developing Strategy
Plavix
Plavix Antitrust Claim
Plavix Consumer Fraud Claims
Plavix Europe
Plavix Iscover
Plavix Litigation
Plavix Litigation Settlement Fails Receive Antitrust Clearance States
Plavix Patent
Plavix Patent Infringement Case
Plavix Patent Litigation
Plavix Product Litigation
Plavix Recovers Position Full Impact Expected
Pneumococcal Program
Pneumococcal Vaccine Program
Pneumoniae
Polio
Polio Haemophilus Influenzae Type Hib
Poliomyelitis
Portfolio
Positive Phase Iib Results Products
Postprandial Glucose Control Apidra
Potentially Maximize Efficacy
Powers
Pre-acquisition Tax Contingencies
Preclinical Studies
Preemptive Rights
Preferential Subscription Rights
Preliminary
Preliminary Injunction Ordered Plavix Patent Infringement Case Apotex
Presentation Alliance Agreements Bms
Presentation Consolidated Financial Statements
Presentation Differences
Presentation Financial Other Information
Presentation Net Sales
Presented Comparability Purposes Though Offer Aventis Transactions Described
Press Release
Press Release Contains Forward-looking Statements Defined Private Securities
Press Release Only Communicated Persons United Kingdom Circumstances
Prevalence Diabetes Increasing Worldwide Number Diabetics Reach 330
Prevention Venous Thrombo-embolic Events Remains Major Public Health
Pricing
Pricing Reimbursement
Pricing Volume Other Restrictions
Principal Accountants Fees Services
Principal Amount Eur
Principal Associates
Principal Financing Transactions
Principal Partnerships
Principal Pharmaceutical Products
Principal Products
Principal Vaccines Products
Principles Internal Control
Pro Forma
Pro Forma Amortization Impairment Intangibles
Pro Forma Combined Developed Sales
Pro Forma Combined Net Sales
Pro Forma Combined Net Sales Business Segment
Pro Forma Combined Net Sales Geographical Region
Pro Forma Combined Net Sales Top Products
Pro Forma Exceptional
Pro Forma Goodwill Amortization
Pro Forma Gross Profit
Pro Forma Income Equity Investees Net
Pro Forma Income Taxes
Pro Forma Information
Pro Forma Minority Interests
Pro Forma Net Financial Income Expense
Pro Forma Net Income
Pro Forma Net Sales
Pro Forma Net Sales Geographic Area
Pro Forma Net Sales Human Vaccines
Pro Forma Statement Income
Procedures Associated Other Executive Operational Support Processes
Procedures Supporting Preparation Chairmans Report
Procter Gamble Pharmaceuticals
Procter Gamble Pharmaceuticals Alliance
Produce Vaccines Meeting Highest Quality Standards
Producing
Product Liability Claims Adversely Affect Business Operating Results
Product Liability Claims Adversely Affect Business Results Operations
Product Overview
Production Raw Materials
Products
Products Committee
Profit-sharing Schemes
Proforma Combined Net Sales Geographical Region
Proforma Statement Income
Progress 2005
Project Boost Innovation
Project Funding
Project Highlights
Property Plant Equipment
Proportionately-consolidated Companies
Prostate Cancer
Protecting Safeguarding
Protection Against Meningococcal Infection
Provided Comparative Purposes Presented Though Offer Aventis Other
Provisions Other Liabilities
Provisions Pensions Other Long-term Benefits
Proxies Votes Mail
Pseudomembranous Colitis Been Reported Nearly Antibacterial Agents Including
Public Accounting Firms
Publication Clinical Trial Results
Published Information Review Committee
Purchase Accounting
Purchase Accounting Effects Primarily Acquisition Aventis 2004
Purchase Own Shares
Purchases Equity Securities Issuer Affiliated Purchasers
Purchasing
Purposes Share Repurchase Programs
Pursued Transformation Strategy Reinforcing Platforms Growth Forging Ahead
Questions Answers
Quorum
Rabies
Rabies Vaccine
Ral Treatment
Ramipril Canada
Ramipril Canada Patent Litigation
Read Important Information End Press Release
Realiseaf
Receive Plavix Clopidogrel Bisulfate
Receive Plavix Clopidogrel Hydrogensulfate
Recent Accounting Pronouncements
Recent Events
Recent Events Associated Offers Aventis Hoechst Shares
Reconciliation 2004 Consolidated Net Sales Pro Forma
Reconciliation 2005 First-half Reported Net Sales Comparable
Reconciliation 2006 First-half Reported Net Sales Comparable
Reconciliation 2007 First-half Reported Net Sales Comparable
Reconciliation 2009 First-half Reported Net Sales Constant Exchange
Reconciliation Carrying Amount Value Redemption
Reconciliation Consolidated Income Statement Adjusted
Reconciliation Consolidated Net Income Adjusted
Reconciliation Consolidated Net Income Attributable Equity Holders Adjusted
Reconciliation First-half Developed Sales 2005 2004
Reconciliation Net Income Adjusted
Reconciliation Net Income Attributable Equity Holders Adjusted
Recordaf
Recorded Video Webcast Presentations Available
Recurrent Major Depression
Redemption Shares
Refer Change Sales Comparable Basis Mean Exclude Impact
References
Refinancing Carried Out 2005
Regarding Zimulti Rimonabant
Regeneron
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Inc
Regenerons Velocisuite Technologies
Registered Capital
Registered Office
Regulation
Regulatory Environment Increasingly Challenging Pharmaceutical Industry
Regulatory Exclusivity
Related Party Transactions
Related-party Transactions
Rely Parties Manufacture Supply Substantial Portion Raw Materials
Rely Parties Marketing Some Products
Rely Parties Marketing Some Products Act Ways Harm
Remain Open Until 2009
Reminder
Renal Cancer
Renal Cell Carcinoma
Replay
Report Chairman Board Directors Preparation Organization Work Internal
Report Independent Registered Public Accounting Firms
Reporting Obligations
Required Reports Pursuant Securities Exchange Act 1934
Requirements Holdings Exceeding Certain Percentages
Research Alliance
Research Development
Research Development Costs Acquired Separately
Research Development Expenses
Research Development Process Lengthy Carries Substantial Risk Product
Research Development Production Activities
Research Development Sites
Research Development Sites Pharmaceutical Activity
Research Development Update
Resolution Plavix Litigation
Respectively Full-year Adjusted Net Income 2005 Was
Respiratory Allergy
Responds Fda Recommendation Influenza Virus Strain Change Supplement
Response Even Those Over Age
Response Global Health Needs Dengue Vaccine
Restructuring Costs
Restructuring Provisions
Result Intensive Development Testing Diabetes Patients Doctors Nurses
Result New Information Future Events Developments
Result Over Intensive Development Testing Designed Pen Input
Results
Results Confirm 2006 Full-year Guidance See Page
Results Guidance
Results Presented Adas Annual Scientific Sessions
Revenue
Revenue Recognition-bms Alliance
Reversal Impairment Loss
Review Portfolio
Rhodia
Rhodia Equity Swap
Rhodia Shareholder Litigation
Right Access Representation
Right Access-representation
Rights Obligations Attached Each Share
Rilutek Litigation
Rilutek Patent Litigation
Rimonabant
Rimonabant Acomplia
Rimonabant Usa Update
Rio-diabetes Study Showed Rimonabant 20mg Significantly Improved Weight
Rio-diabetes Trial
Risk Factors
Risks Handling Hazardous Materials Adversely Affect Operating Results
Risks Handling Hazardous Materials Adversely Affect Results Operations
Role
Role Board Directors
Role Internal Control Assessment Department
Roles Powers Chairman Chief Executive Officer
Russia National Project Health
S-1
Sabril Litigation
Sabril Litigation Anti-epilepsy
Safety
Safety Efficacy Data Presented 2009 Ectrims
Safety Information
Safety Information Influenza H1n1 2009 Monovalent Vaccine
Safety Tolerability
Sales
Sales Active Ingredient American Joint Venture Managed Bms
Sales Shares Cause Market Price Adss Decline
Sales Shares Eligible Sale Near Future Cause Market
Salk Institute Biological Studies
San Diego 2005
Sanofi Aventis Pfizer Seek Approval Market Exubera United
Sanofi Pasteur
Sanofi Pasteur Begins Shipping Adacel Vaccine Combined Protection
Sanofi Pasteur Blood Products Litigation
Sanofi Pasteur China
Sanofi Pasteur Clinical Trial Design
Sanofi Pasteur Crucell Exclusive Agreement
Sanofi Pasteur Dengue Vaccine Global Clinical Study Program
Sanofi Pasteur Hepatitis Vaccine Litigation
Sanofi Pasteur Inc Thimerosal Litigation
Sanofi Pasteur Influenza Vaccine Production
Sanofi Pasteur Mmr Vaccine Litigation
Sanofi Pasteur Pandemic Preparedness
Sanofi Pasteur Pipeline
Sanofi Pasteur Sites
Sanofi Pasteur Thimerosal Litigation
Sanofi-aventis
Sanofi-aventis 2005 First-half Consolidated Income Statement
Sanofi-aventis Acquire Fovea French Biopharmaceutical Ophthalmology
Sanofi-aventis Acquires 24876 Zentiva
Sanofi-aventis Also Excludes Integration Restructuring Costs Associated Transaction
Sanofi-aventis Brazil
Sanofi-aventis Cardiology Thrombosis
Sanofi-aventis China
Sanofi-aventis Committed Working Diabetes Community Develop New Technologies
Sanofi-aventis Concludes Euro10 Medium-term Credit Agreements Banks Refinance
Sanofi-aventis Delivers 2008 Results Above Guidance
Sanofi-aventis Excludes Adjusted Net Income Restructuring Cost Associated
Sanofi-aventis Forward Looking Statements
Sanofi-aventis Forward-looking Statements
Sanofi-aventis Gains Market Share
Sanofi-aventis Group
Sanofi-aventis Group Conducts Business Through Affiliates Sanofi-synthelabo Inc
Sanofi-aventis Group Subsidiaries United States Include Sanofi-synthelabo Inc
Sanofi-aventis Mexico
Sanofi-aventis Oncology Target Cancer Commitment Action
Sanofi-aventis Parent Financial Statements 2006 French Gaap
Sanofi-aventis Parent Financial Statements Half 2005 French Gaap
Sanofi-aventis Partnership Fighting Against Neglected Diseases
Sanofi-aventis Pen Portfolio
Sanofi-aventis Pro Forma Income Statement 2004
Sanofi-aventis Research Development Achievements 2007
Sanofi-aventis Research Development Achievements 2008
Sanofi-aventis Research Development Diabetes
Sanofi-aventis Scientific Medical Affairs Achievements 2004
Sanofi-aventis Scientific Medical Affairs Achievements 2005
Sanofi-aventis Scientific Medical Affairs Achievements 2006
Sanofi-aventis Simplified Consolidated Balance Sheet
Sanofi-aventis Simplified Statement Cash Flows
Sanofi-aventis Statement
Sanofi-aventis Subsidiaries United States Include Sanofi-synthelabo Inc Aventis
Sanofi-aventis Sues Novopharm Patent Infringement Canada
Sanofi-aventis Transformation Program
Sanofi-aventiss Largest Shareholders Own Significant Percentage Enlarged Share
Schering-plough
Schizophrenia Serious Psychiatric Condition Affecting Around Adult Population
Scope Ims Developed Sales Includes
Scope Internal Control
Searching Discovering Developing Registering New Products
Seasonal Influenza Overview
Seasonal Pandemic Influenza Vaccines
Seasonal Trends
Securities Offered Not Been Registered Act 1933 Amended
Securities Registered Pursuant Act
See Adverse Reactions
See Appendix Definitions Financial Indicators Page Details Selected
See Appendix Geographical Split Consolidated Net Sales Product
See Warnings
Segmental Analysis
Selected Exchange Rate Information
Selected Refer Appendix
Selected See Appendix
Selling General Expenses
Senior Management
Senior Vice President Audit Internal Control Assessment
Senior Vice President Business Development
Senior Vice President Chief Financial Officer
Senior Vice President Chief Medical Officer
Senior Vice President Communications Institutional Professional Relations
Senior Vice President Corporate Affairs
Senior Vice President Corporate Human Resources
Senior Vice President Global Marketing
Senior Vice President Global Marketing Access
Senior Vice President Human Resources Since 2008
Senior Vice President Industrial Affairs
Senior Vice President Industrial Affairs Since 2008
Senior Vice President International Development
Senior Vice President Legal Affairs General Counsel
Senior Vice President Pharmaceutical Operations Asia Pacific
Senior Vice President Pharmaceutical Operations Asia Pacific Japan
Senior Vice President Pharmaceutical Operations Europe Canada Excluding
Senior Vice President Pharmaceutical Operations France
Senior Vice President Pharmaceutical Operations Intercontinental
Senior Vice President Pharmaceutical Operations United States
Senior Vice President Research Development
Senior Vice President Vaccines
Serenade
Serge Weinberg
Series Participating Shares
Settlement
Shanghai Institutes Biological Sciences Sibs
Share Buyback Program
Share Capital
Share Issue Reserved Employees
Share Ownership
Share Profit Associates
Share Profit Loss Associates
Share Profits Associates
Share Repurchase Program
Share Repurchase Program Dividend
Share Repurchase Programs
Share Warrants
Share-based Payment
Shareholders Agreement
Shareholders Equity
Shares Adss
Shares Eligible Future Sale
Shares Owned Members Board Directors
Shares Owned Members Board Directors Executive Committee
Shares Owned Members Board Directors Senior Management
Sharp Rise Proposed Dividend
Shipment Fluzone Influenza Virus Vaccine Market Begins-
Short-term Debt Current Portion Long-term
Sickness Fexinidazole
Signatures
Significant Acquisitions
Significant Changes
Significant Changes 2002
Significant Changes 2003
Significant Changes 2005
Significant Changes 2005 2006
Significant Changes Half 2005
Significant Divestments
Significant Post Balance Sheet Events
Significant Progress Pipeline
Signing Take Place Franco-russian Intergovernmental Seminar
Simplified Consolidated Balance Sheet
Simplified Consolidated Statement Cash Flows
Simplifying Administration Acute Coronary Syndrome Patients
Sleeping Sickness Human African Trypanosomiasis Hat
Slowdown Global Economic Growth Negative Consequences Business
Social Charter
Société Anonyme Conseil Dadministration
Solid Quarterly Results 2009 Full-year Guidance Updated
Solostar
Solostar Patent Litigation
Some 300 People Suffer Dyslipidemia Largest Industrialized Countries
Sorbates Industry Investigation
Source Sdi 2005 Update
Sources Revenues Expenses
Spain
Specialist Committees
Spirits Study
Split Business Segment
Split Net Sales
Ssr 591813 Smoking Cessation
Stake Regeneron Approximately
Standards
Standards Amendments Applicable Consolidated Financial Statements Sanofi-aventis
Standards Amendments Not Apply Consolidated Financial Statements Sanofi-aventis
Staphylococcus Aureus
State Local Taxes
Statement Corporate Governance Required 303a-11 New York Stock
Statement Corporate Governance Required Rule 303a11 New York
Statements Cautionary Factors
Statistical Analysis
Status Owner
Statutory Auditors
Statutory Profit-sharing Scheme Participation Des Salariés Aux Résultats
Statutory Scheme Participation Des Salariés Aux Résultats Lentreprise
Stemi Acute Coronary Syndrome
Stilnox Ambien Myslee
Stilnox Zolpidem Product Litigation
Stock Market Risk
Stock Option Plans
Stock Option Plans Share Warrants
Stock Options
Stock Options Exercised Directors Employees
Stock Options Held Jean-françois Dehecq
Stock Options Warrants
Stock Purchase Option Plans
Stock Subscription Option Plan Granted Sanofi-aventis
Stock Subscription Option Plans
Stock-based Compensation
Strategy
Strategy Committee
Strengthen Creativity Innovation
Streptococcus Pneumoniae
Strong Cash Flow Operating Activities Half 2009
Strong Growth 257 2005 Adjusted Eps Nearly Synergies
Studies
Studies Support Safety Immunogenicity
Study
Study Design
Study Designs
Study Findings
Study Results
Study Suggests Rimonabant Achieve Improvement Blood Glucose Added
Subject Various Risks
Submission
Summarized Financial Information Related Equity Investees
Summary Not Constitute Legal Tax Advice Holders Consult
Summary Selected Financial Data
Summary Selected Historical Consolidated Financial Data Sanofi-aventis Aventis
Summary Stock Option Plans
Sunday 500 515 Hall Oral Presentation
Supplements
Survival Rates Advanced Head Neck Cancer Historically Been
Survival Update Prognostic Factor Analysis Oxaliplatin Irinotecan Iri
Sustainable Development Health Safety Environment Hse
Sustained Sales Growth
Swiftwater Lyon France 2005
Swiftwater Lyon France 2006
Swiftwater Lyon France 2007
Swissmedic
Symbion Consumer
Symptomatic Malignant Ascites
Syndrome
Table Below Shows Key First-half Figures
Taiho
Targeted Partnerships Support Development Innovative Products
Tax 325 Study
Tax 327 Study
Tax Sale Other Disposition
Tax Sale Other Disposition Including Redemption
Taxation Annual Payments
Taxation Annual Payments Reorganization Payment
Taxation Dividends
Taxation Redemption
Taxes
Taxotere
Taxotere Now Approved Cancer Types Japan-
Taxotere Patent Litigation
Taxotere Receives Fda Approval Treatment Patients Head Neck
Team Research Worlds Largest Vaccine Manufacturers Combination Parties
Telephone
Telithromycin
Teriflunomide
Term
Tetani
Tetanus
Teva
Teva Pharmaceutical Industries
Teva Pharmaceuticals
Teva Safe Harbor Statement Private Securities Litigation Reform
Thailand Scientific Milestone
Then Named Gérard Fur Chief Executive Officer Jean-françois
They Colleagues Study Rather Research Subjects
Thrombosis
Thrombosis Diabetes Cardiovascular Unique Portfolio Most Promising Industry
Thursday 2007
Time Compared Placebo
Timing Payment
Timothy Rothwell
Tnbc
Tokyo Japan Paris France 2006
Top Products
Trademarks
Trading Eurolist Market
Trading Euronext Paris Market
Trading Own Shares
Trading Practices Own Shares
Transactions Associates
Transactions Directors Materially Interested
Transactions Shares Members Board Directors
Transfer Rights Exubera Interest Diabel
Transfer Shares
Transformation Sanofi-aventis
Transforming Sanofi-aventis Diversified Global Leader Healthcare
Transition Ifrs
Travel Endemic Measles Mumps Rubella Mmr Vaccines
Travel Endemic Vaccines
Treasury Shares
Treat Type Diabetes
Treatment Legacy Bsas
Treatment Milestone Payments Licensing Agreements
Treatments People Living Type Diabetes
Trial Demonstrates Optimal Therapeutic Index Patients Tch Did
Trials Vte Prevention Atrial Fibrillation Patients
Triple Negative Breast Cancer Tnbc
Tritace
Tritace Triatec Delix Altace
Trovax
Tuberculosis
Types Stock Options
Ucb
Ucb Forward-looking Statement
Unable Protect Proprietary Rights Compete Effectively Operate Profitably
Unable Protect Proprietary Rights Fail Compete Effectively Operate
Unable Protect Proprietary Rights Not Compete Effectively Operate
United Kingdom
United States
University California Berkeley
Unless Otherwise Indicated Growth Figures Press Release Comparable
Unless Otherwise Indicated Sales Growth Figures Press Release
Update
Update Caption Armour Blood Products Litigation D201 Consolidated
Update Caption Government Investigations Pricing Marketing Practices D201
Update Caption Lovenox Patent Litigation D22b Consolidated Financial
Update Caption Plavix Patent Litigation D22b Consolidated Financial
Update Caption Ramipiril Canada D201 Consolidated Financial Statements
Update Caption Rhodia D201 Consolidated Financial Statements Included
Update Caption Sanofi Pasteur Inc Thimerosal Litigation D22a
Update Caption Solostar Patent Litigation D22b Consolidated Financial
Vaccine Combined Protection Against Tetanus Diphtheria Pertussis
Vaccine Government
Vaccine Shan5 Dtp Hib Hepb
Vaccines
Vaccines Clinical Results Meet Major Public Health Needs
Vaccines Products
Vaccines Research Development
Valuation Methods
Van Gogh Dvt Trials
Van Gogh Extension Trials
Various Cancer Types Stages Disease Data Suggest Product
Vegf Trap Clinical Development Program Oncology
Vegf Trap Represent New Treatment Regimen Seriously Ill
Venous Thromboembolism Vte
Vice President Chemistry
Vienna Austria 2006
Vitamin Antitrust Litigation
Voluntary Scheme Intéressement Des Salariés
Votes Required Shareholder Action
Voting Rights
Wacker Chemie
Wacker-chemie
Warrants
Was Prepared Basis Following Principles
Wayne Pisano
Wealth Tax
Well-controlled Patients Derive Benefit Switch Lantus
Wellstat Therapeutics
West Nile Virus Infections
While Adding Late Stage Development Portfolio
Wiftwater Lyon France 2006
Working Capital Needs Increased 1281163 Period Compared 1281076
World Heart Federation
Worlds Largest Diabetes Genotyping Project
Worldwide Comparable-basis Sales Plavix Aprovel 2007 2006 Split
Worldwide Comparable-basis Sales Plavix Aprovel 2008 2007 Split
Worldwide Presence Aprovel Avapro Karvea
Worldwide Presence Plavix Aprovel
Worldwide Presence Plavix Iscover
Worldwide Presence Product
Xaliproden Severe Peripheral Sensory Neuropathy Psn Induced Chemotherapy
Xatral
Xatral Patent Litigation
Xatral Uroxatral
Xl147 Xl765
Xyzal
Xyzal New Treatment Option Todays Challenging Allergy Environment
Xyzal Tablets Anda
Yves Rocher
Zentiva
Zentiva Approximately 128
Zentiva Offer
Zentiva Shareholders Until 2009 Tender Shares
Zimulti Acomplia Rimonabant Class Action
Zimulti Rimonabant Class Action
Skip the spreadsheet. Track your investments automatically.
Start now